CN101474388A - 一种改进的仙蟾片药物处方及其制备方法 - Google Patents
一种改进的仙蟾片药物处方及其制备方法 Download PDFInfo
- Publication number
- CN101474388A CN101474388A CNA200810236557XA CN200810236557A CN101474388A CN 101474388 A CN101474388 A CN 101474388A CN A200810236557X A CNA200810236557X A CN A200810236557XA CN 200810236557 A CN200810236557 A CN 200810236557A CN 101474388 A CN101474388 A CN 101474388A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- toad
- sheet
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241000269417 Bufo Species 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 55
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 12
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 8
- 241001522129 Pinellia Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 241000208340 Araliaceae Species 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 241001446509 Psoralea Species 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 235000016993 Agrimonia Nutrition 0.000 claims description 7
- 235000014375 Curcuma Nutrition 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000007598 dipping method Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- -1 electuary Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000003088 amphibian venom Substances 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000107975 Strychnos nux-vomica Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 43
- 239000008280 blood Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 31
- 201000009030 Carcinoma Diseases 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 15
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 229960004397 cyclophosphamide Drugs 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 9
- 239000003172 expectorant agent Substances 0.000 description 9
- 230000003419 expectorant effect Effects 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 240000002853 Nelumbo nucifera Species 0.000 description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 241000407170 Curcuma Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001415432 Duttaphrynus melanostictus Species 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000026 apposition eye Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical group CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009177 immunoglobulin therapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
分类 | 例数(1) (2) | 完全缓解(例%)(1) (2) | 部分缓解(例%)(1) (2) | 稳定(例%)(1) (2) | 无效(例%)(1) (2) | 有效率(%)(1) (2) | P值 |
肺癌食道癌胃癌肝癌肠癌脑瘤膀胱癌总计 | 135 2996 2572 2562 1623 1420 1217 11425 132 | 57(42) 11(38)40(42) 10(40)22(31) 6(24)21(35) 5(31)9(40) 4(29)7(37) 4(33)5(29) 2(18)161(38) 42(32) | 55(41) 7(25)38(40) 5(20)30(42) 7(30)21(33) 5(29)6(26) 4(27)10(48) 2(21)8(47) 4(36)168(40) 34(25) | 18(13) 6(22)11(11) 5(22)15(20) 5(20)10(17) 3(19)7(30) 5(34)1(5) 3(25)3(18) 3(27)65(15) 30(23) | 5(4) 5(15)7(7) 5(18)5(7) 7(26)10(15) 3(19)1(4) 1(10)2(10) 3(21)1(6) 2(19)31(7) 26(20) | 83 6281 6072 5268 6265 5785 5076 5577.4 57.6 | <0.05<0.05<0.05<0.05<0.05<0.05<0.05<0.05 |
症状 | 精神萎靡(1) (2) | 形体消瘦(1) (2) | 心悸怔忡(1) (2) | 气短乏力(1) (2) | 头晕耳鸣(1) (2) | 腰背疼痛(1) (2) | 遗精阳萎(1) (2) | ***(1) (2) | 恶心呕吐(1) (2) | 疼痛(1) (2) |
治疗前治疗后有效率(%) | 421 120281 10533.3 12.5 | 409 104289 9929.3 4.8 | 375 96194 9248.3 42 | 375 103220 9441.3 8.7 | 361 87226 8337.4 4.6 | 285 107125 9356.1 13.1 | 148 5654 5236.5 7.1 | 107 2752 2351.4 14.8 | 361 105221 10338.8 1.9 | 419 103279 9133.4 11.7 |
组别 | 剂量 | 动物数 | OD(540nm) |
(mg/kg) | (n) | ||
生理盐水组 | 14 | 0.63±0.10 | |
仙蟾片小剂量组(原处方) | 250 | 12 | 0.65±0.12 |
仙蟾片大剂量组(原处方) | 500 | 12 | 1.04±0.09* |
仙蟾片小剂量组(新处方) | 250 | 12 | 0.68±0.10 |
仙蟾片大剂量组(新处方) | 500 | 12 | 1.03±0.08* |
左旋咪唑 | 2.4 | 12 | 0.66±0.06 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810236557A CN101474388B (zh) | 2008-12-31 | 2008-12-31 | 一种改进的仙蟾片药物处方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810236557A CN101474388B (zh) | 2008-12-31 | 2008-12-31 | 一种改进的仙蟾片药物处方及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101474388A true CN101474388A (zh) | 2009-07-08 |
CN101474388B CN101474388B (zh) | 2012-08-29 |
Family
ID=40835216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810236557A Active CN101474388B (zh) | 2008-12-31 | 2008-12-31 | 一种改进的仙蟾片药物处方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101474388B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106421647A (zh) * | 2016-10-25 | 2017-02-22 | 黄赵玲 | 净身排毒的瑶药外用桶浴药液及其制备方法 |
CN106511874A (zh) * | 2016-10-27 | 2017-03-22 | 金秀瑶族自治县瑶医医院 | 具有排毒养颜功效的瑶药保健浴包及其制备方法 |
CN111210917A (zh) * | 2019-12-30 | 2020-05-29 | 北京左医健康技术有限公司 | 基于线下扫码的用药指导方法和*** |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384465C (zh) * | 2005-05-24 | 2008-04-30 | 赵东科 | 一种治疗癌瘤的中药制剂及制备方法 |
CN100542523C (zh) * | 2006-05-06 | 2009-09-23 | 安徽科创中药天然药物研究所有限责任公司 | 仙蟾胶囊及其制备方法、质量控制方法 |
-
2008
- 2008-12-31 CN CN200810236557A patent/CN101474388B/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106421647A (zh) * | 2016-10-25 | 2017-02-22 | 黄赵玲 | 净身排毒的瑶药外用桶浴药液及其制备方法 |
CN106511874A (zh) * | 2016-10-27 | 2017-03-22 | 金秀瑶族自治县瑶医医院 | 具有排毒养颜功效的瑶药保健浴包及其制备方法 |
CN111210917A (zh) * | 2019-12-30 | 2020-05-29 | 北京左医健康技术有限公司 | 基于线下扫码的用药指导方法和*** |
Also Published As
Publication number | Publication date |
---|---|
CN101474388B (zh) | 2012-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101711848B (zh) | 一种辅助***的中药组合物 | |
CN107375815A (zh) | 一种治疗消化道肿瘤的中药 | |
CN102078569A (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN101474388B (zh) | 一种改进的仙蟾片药物处方及其制备方法 | |
CN103100025A (zh) | 一种益肾壮阳的药物组合物及其制备方法 | |
CN103623280B (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN105213974A (zh) | 一种治疗淋巴瘤的中药组合物及其应用 | |
CN101564464B (zh) | 一种调节肿瘤患者机体免疫力的中药药物 | |
CN101347543A (zh) | 一种中药组合物及其制备方法 | |
CN1284599C (zh) | 一种消肿瘤的药物及其制备工艺 | |
CN108186794A (zh) | 一种治疗恶性肿瘤的中药组合物及其制备方法和应用 | |
CN102058854B (zh) | 治疗恶性淋巴瘤的中药 | |
CN104027447B (zh) | 一种治疗癌症的中药 | |
CN104825817A (zh) | 一种具有抗肿瘤作用的中药制剂 | |
CN104840864B (zh) | 一种治疗小儿脾虚型腹泻的中药制剂 | |
CN109078157A (zh) | 一种抗肿瘤药物及其制备方法 | |
CN114404490B (zh) | 用于***放化疗后白细胞减少症的中药及制备方法 | |
CN102961704A (zh) | 一种用于治疗肝癌的药物组合物及其分散片制备方法 | |
CN1194717C (zh) | 治疗肺癌的蛇毒胶囊及制备方法 | |
CN100443093C (zh) | 治疗艾滋病的药物 | |
CN101991645A (zh) | 一种治疗冠心病的制剂及制备方法 | |
CN101007114B (zh) | 一种肿瘤患者辅助用药品或保健品及其制备方法 | |
CN105920436A (zh) | 一种用于治疗肺癌的药物制剂及其制备方法 | |
CN107362296B (zh) | 治疗皮肤良性肿瘤的药物及其制备方法 | |
CN101229272A (zh) | 一种提高免疫力的药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DONGKE MAIDISEN PHARMACEUTICAL CO., LTD., YANGLING Free format text: FORMER OWNER: ZHAO DONGKE Effective date: 20130628 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 712100 XI AN, SHAANXI PROVINCE TO: 712100 XIANYANG, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130628 Address after: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee after: Dongke Maidisen Pharmaceutical Co., Ltd., Yangling Address before: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi, Xi'an Patentee before: Zhao Dongke |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI DONGKE PHARMACEUTICAL LLC Free format text: FORMER OWNER: DONGKE MAIDISEN PHARMACEUTICAL CO., LTD., YANGLING Effective date: 20141230 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141230 Address after: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee after: SHAANXI DONGKE PHARMACEUTICAL CO., LTD. Address before: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee before: Dongke Maidisen Pharmaceutical Co., Ltd., Yangling |